Aktiesnakken — Marts 2010
-
genmab nyt
-
Genmab announces top-line results from a study of zalutumumab in
refractory head and neck cancer patients who failed platinum based
chemot -
-
76-77
-
det var godt nok skuffende
-
hmmmm
-
jo 83
på heefbooms -
det kostede lige kassen
-
men er dog bedre end det lort der sker lige nu
-
-23%... hvorfor går den ikke i børspuse?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind